Coya Therapeutics, Inc. Stock Price, News & Analysis

Coya Therapeutics (NASDAQ: COYA) announced that company management will participate in two investor and scientific conferences on December 2, 2025. CEO Dr. Arun Swaminathan will appear in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami from 8:45–9:05 am ET with a live webcast available.

CMO Dr. Fred Grossman will join a roundtable at the 18th CTAD Conference in San Diego from 3:10–3:50 pm ET titled “Charting the Path Forward for Combination Therapy in Alzheimer’s Disease.” Webcasts and archived replays will be available on the company’s Investor Relations Events and Presentations page, with replays accessible for 90 days.

ReAlta Life Sciences (AVIR) appointed Howard Berman, Ph.D. as Executive Chairman effective immediately on November 25, 2025. The company said Dr. Berman brings more than 20 years of biopharma leadership across company formation, clinical development, strategic partnerships, and public-market execution.

ReAlta highlighted pegtarazimod's clinical data and safety profile across three life-threatening diseases and said the peptide platform targets complement and neutrophil-driven inflammation. Dr. Berman currently chairs Coya Therapeutics and serves on the board of Atea Pharmaceuticals.

Coya Therapeutics (NASDAQ: COYA) launched the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled 24-week study of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) (ClinicalTrials.gov: NCT 07161999).

The study will enroll 120 participants across approximately 25 centers in the United States and Canada. Participants completing the 24-week placebo-controlled phase may join a 24-week blinded extension during which all participants will receive COYA 302 at one of two prespecified doses. Study details and eligibility are available on the trial registry. The trial will be presented on September 29, 2025 during a NEALS educational webinar.

Coya Therapeutics (NASDAQ: COYA) reported Q3 2025 results and a corporate update: the FDA accepted the IND for COYA 302 in ALS and Coya launched the Phase 2 ALSTARS trial (NEALS-affiliated). The company received a $4.2M milestone from Dr. Reddy’s and closed an upsized public offering of $23.0M, extending cash runway into 2H 2027. Cash and equivalents were $28.1M at September 30, 2025. Q3 collaboration revenue was $3.6M (including $3.3M license revenue on IND acceptance). R&D expenses were $2.9M, G&A $2.6M, and net loss was $2.1M for the quarter.

Coya Therapeutics (NASDAQ: COYA) reported results from a completed in vivo mouse study of its investigational combination COYA 303 (low-dose IL-2 + GLP-1 receptor agonist) in a lipopolysaccharide (LPS) model of systemic and neurologic inflammation on November 4, 2025. The company said COYA 303 reduced peripheral pro-inflammatory cell expansion, enhanced regulatory T cell (Treg) activation and function, attenuated CNS inflammation, and shifted monocytes/macrophages toward an anti-inflammatory phenotype versus controls.

Coya noted the study confirmed interim findings, used daily LPS injections for five days with COYA 303 given for four days, and plans to publish a full dataset. Management linked these preclinical effects to potential development in neurodegenerative and autoimmune diseases and referenced upcoming semaglutide Alzheimer’s trial readouts as strategic context.

Coya Therapeutics (NASDAQ: COYA) closed an underwritten public offering raising approximately $23.0 million through the sale of 4,181,818 shares of common stock at a public offering price of $5.50 per share, including 545,454 additional shares sold upon full exercise of the underwriter’s option.

The company said gross proceeds were approximately $23.0 million before underwriting discounts, commissions, and offering expenses. Coya intends to use net proceeds for working capital, general corporate purposes, and to fund its clinical development plan. Lucid Capital Markets served as book-running manager.

Coya Therapeutics (NASDAQ: COYA) priced an underwritten public offering of 3,636,364 shares of common stock at $5.50 per share, with gross proceeds expected to be approximately $20.0 million. The company granted the underwriter a 30-day option to purchase up to 545,454 additional shares at the offering price, subject to underwriting discounts and commissions.

The offering is expected to close on or about October 27, 2025, subject to customary closing conditions. Net proceeds are intended for working capital and general corporate purposes, including funding Coya's clinical development plan. The shares are offered under a Form S-3 shelf registration declared effective August 19, 2025.

Coya Therapeutics (NASDAQ: COYA) announced a proposed underwritten public offering of common stock on October 23, 2025.

The offering may include a 30-day underwriter option to purchase up to an additional 15% of the shares at the offering price, less discounts and commissions. Proceeds are intended for working capital and clinical development. Lucid Capital Markets is sole book-running manager.

The offering is being made under a shelf registration statement on Form S-3 (File No. 333-289511) declared effective by the SEC on August 19, 2025; final terms will be disclosed in a prospectus supplement and are subject to market and other conditions.

Coya Therapeutics (NASDAQ: COYA) congratulated scientific advisor Dr. Shimon Sakaguchi on receiving the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). The company noted Dr. Sakaguchi’s long-standing advisory role guiding Coya’s strategy to harness and enhance Treg biology for therapies targeting immune dysfunction. Coya emphasized the Nobel recognition as validation of Treg science and said it remains committed to advancing therapies inspired by that discovery.